Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens: a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa
The World Health Organization-approved Xpert MTB/XDR test detects Mycobacterium tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and injectable drugs directly in specimens. This pragmatic, laboratory-based study assessed the diagnostic accuracy and feasibility of a reflex tes...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2024
|
| In: |
Open Forum Infectious Diseases
Year: 2024, Jahrgang: 11, Heft: 8, Pages: 1-10 |
| ISSN: | 2328-8957 |
| DOI: | 10.1093/ofid/ofae437 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/ofid/ofae437
|
| Verfasserangaben: | C.M. Centner, R. Munir, E. Tagliani, F. Rieß, P. Brown, C. Hayes, T. Dolby, W. Zemanay, D.M. Cirillo, A. David, S.G. Schumacher, C.M. Denkinger, M. Ruhwald, V.N. Leukes, M.P. Nicol, I. Van der Walt, G. Kisten, M. Gumede, A. Mace, A. Brink, W. Stevens, L. Scott, A. Penn-Nicholson, H. Cox, on behalf of the TB-CAPT Consortium |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1930199813 | ||
| 003 | DE-627 | ||
| 005 | 20250710113659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250710s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofae437 |2 doi | |
| 035 | |a (DE-627)1930199813 | ||
| 035 | |a (DE-599)KXP1930199813 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Centner, Chad |e VerfasserIn |0 (DE-588)1371129754 |0 (DE-627)1930200552 |4 aut | |
| 245 | 1 | 0 | |a Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens |b a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa |c C.M. Centner, R. Munir, E. Tagliani, F. Rieß, P. Brown, C. Hayes, T. Dolby, W. Zemanay, D.M. Cirillo, A. David, S.G. Schumacher, C.M. Denkinger, M. Ruhwald, V.N. Leukes, M.P. Nicol, I. Van der Walt, G. Kisten, M. Gumede, A. Mace, A. Brink, W. Stevens, L. Scott, A. Penn-Nicholson, H. Cox, on behalf of the TB-CAPT Consortium |
| 264 | 1 | |c August 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 31. Juli 2024 | ||
| 500 | |a Gesehen am 10.07.2025 | ||
| 520 | |a The World Health Organization-approved Xpert MTB/XDR test detects Mycobacterium tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and injectable drugs directly in specimens. This pragmatic, laboratory-based study assessed the diagnostic accuracy and feasibility of a reflex testing approach, where Xpert MTB/XDR was performed on residual specimens previously processed for Xpert MTB/RIF Ultra.Routine respiratory specimens, processed for Xpert MTB/RIF Ultra, were stored in sample reagent buffer at 2°C-8°C. If rifampicin resistant, the residual specimen was assessed for adequate volume (≥2 mL) and tested with Xpert MTB/XDR, with storage time recorded. A second specimen was used for routine and reference standard testing (culture and sequencing).Specimens (99% sputum) from 763 participants submitted to 2 large routine laboratories were included. Xpert MTB/XDR yielded valid resistance detection results in 639 (84%), compared with 507 (66%) for routine testing (difference [95% CI], 18% [13%-22%]). The median turnaround time for results was 23 hours for Xpert MTB/XDR and 15 days for routine testing. While 748 specimens (98%) were ≥2 mL, only 102 (13%) were stored for ≤4 hours. By the reference standard, 284 of 394 (72%) were isoniazid resistant, and 57 of 380 (15%) were fluroquinolone resistant. The sensitivities of Xpert MTB/XDR were 94% (95% CI, 91%-97%) for isoniazid and 91% (81%-97%) for fluoroquinolone resistance detection. The specificities were 98% (94%-100%) and 100% (98%-100%), respectively.Xpert MTB/XDR performed favorably compared with the reference, and the reflex testing approach increased results availability over routine testing, while dramatically decreasing turnaround time from weeks to hours. Laboratory workflow precluded testing within the manufacturer-recommended 4-hour storage time, but longer storage did not appear detrimental. | ||
| 700 | 1 | |a Munir, R |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tagliani, E |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rieß, F |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brown, P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hayes, C |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dolby, T |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zemanay, W |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cirillo, D M |e VerfasserIn |4 aut | |
| 700 | 1 | |a David, A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schumacher, S G |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkinger, Claudia M. |d 1978- |e VerfasserIn |0 (DE-588)131597701 |0 (DE-627)511279469 |0 (DE-576)298613727 |4 aut | |
| 700 | 1 | |a Ruhwald, M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leukes, V N |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nicol, M P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Van der Walt, I |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kisten, G |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gumede, M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mace, A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brink, A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stevens, W |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scott, L |e VerfasserIn |4 aut | |
| 700 | 1 | |a Penn-Nicholson, A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cox, H |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open Forum Infectious Diseases |d Oxford : Oxford University Press, 2014 |g 11(2024), 8 vom: Aug., Artikel-ID ofae437, Seite 1-10 |h Online-Ressource |w (DE-627)779394089 |w (DE-600)2757767-3 |w (DE-576)401709566 |x 2328-8957 |7 nnas |a Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:8 |g month:08 |g elocationid:ofae437 |g pages:1-10 |g extent:10 |a Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa |
| 856 | 4 | 0 | |u https://doi.org/10.1093/ofid/ofae437 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250710 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 131597701 |a Denkinger, Claudia M. |m 131597701:Denkinger, Claudia M. |d 910000 |d 911700 |d 50000 |e 910000PD131597701 |e 911700PD131597701 |e 50000PD131597701 |k 0/910000/ |k 1/910000/911700/ |k 0/50000/ |p 12 | ||
| 999 | |a KXP-PPN1930199813 |e 4744545106 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Veröffentlicht: 31. Juli 2024","Gesehen am 10.07.2025"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 07.08.2020"],"pubHistory":["2014 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title":"Open Forum Infectious Diseases","title_sort":"Open Forum Infectious Diseases"}],"recId":"779394089","disp":"Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens a clinical laboratory-based diagnostic accuracy and feasibility study in South AfricaOpen Forum Infectious Diseases","id":{"issn":["2328-8957"],"zdb":["2757767-3"],"eki":["779394089"]},"origin":[{"publisherPlace":"Oxford","dateIssuedDisp":"2014-","publisher":"Oxford University Press","dateIssuedKey":"2014"}],"part":{"year":"2024","issue":"8","volume":"11","pages":"1-10","text":"11(2024), 8 vom: Aug., Artikel-ID ofae437, Seite 1-10","extent":"10"}}],"person":[{"given":"Chad","role":"aut","family":"Centner","display":"Centner, Chad"},{"display":"Munir, R","given":"R","role":"aut","family":"Munir"},{"display":"Tagliani, E","family":"Tagliani","role":"aut","given":"E"},{"family":"Rieß","role":"aut","given":"F","display":"Rieß, F"},{"display":"Brown, P","role":"aut","given":"P","family":"Brown"},{"family":"Hayes","given":"C","role":"aut","display":"Hayes, C"},{"role":"aut","given":"T","family":"Dolby","display":"Dolby, T"},{"given":"W","role":"aut","family":"Zemanay","display":"Zemanay, W"},{"family":"Cirillo","given":"D M","role":"aut","display":"Cirillo, D M"},{"role":"aut","given":"A","family":"David","display":"David, A"},{"family":"Schumacher","role":"aut","given":"S G","display":"Schumacher, S G"},{"display":"Denkinger, Claudia M.","family":"Denkinger","role":"aut","given":"Claudia M."},{"display":"Ruhwald, M","given":"M","role":"aut","family":"Ruhwald"},{"role":"aut","given":"V N","family":"Leukes","display":"Leukes, V N"},{"display":"Nicol, M P","family":"Nicol","role":"aut","given":"M P"},{"family":"Van der Walt","given":"I","role":"aut","display":"Van der Walt, I"},{"display":"Kisten, G","family":"Kisten","role":"aut","given":"G"},{"display":"Gumede, M","family":"Gumede","given":"M","role":"aut"},{"family":"Mace","role":"aut","given":"A","display":"Mace, A"},{"role":"aut","given":"A","family":"Brink","display":"Brink, A"},{"role":"aut","given":"W","family":"Stevens","display":"Stevens, W"},{"display":"Scott, L","family":"Scott","given":"L","role":"aut"},{"given":"A","role":"aut","family":"Penn-Nicholson","display":"Penn-Nicholson, A"},{"display":"Cox, H","family":"Cox","given":"H","role":"aut"}],"title":[{"title_sort":"Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens","title":"Reflex Xpert MTB/XDR testing of residual Rifampicin-resistant specimens","subtitle":"a clinical laboratory-based diagnostic accuracy and feasibility study in South Africa"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"id":{"eki":["1930199813"],"doi":["10.1093/ofid/ofae437"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"August 2024"}],"name":{"displayForm":["C.M. Centner, R. Munir, E. Tagliani, F. Rieß, P. Brown, C. Hayes, T. Dolby, W. Zemanay, D.M. Cirillo, A. David, S.G. Schumacher, C.M. Denkinger, M. Ruhwald, V.N. Leukes, M.P. Nicol, I. Van der Walt, G. Kisten, M. Gumede, A. Mace, A. Brink, W. Stevens, L. Scott, A. Penn-Nicholson, H. Cox, on behalf of the TB-CAPT Consortium"]},"recId":"1930199813"} | ||
| SRT | |a CENTNERCHAREFLEXXPER2024 | ||